Tumor-agnostic drug development in dMMR/MSI-H solid tumors
Trends in Cancer · 2023-10 · 9 (10) · 828-839
DOI: 10.1016/j.trecan.2023.07.002 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Trends in Cancer, 2023-10. Verfasst von Deepak Bhamidipati und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 95 Literaturangaben. Gefördert von: NCI.
Abstract (Originalsprache)
Mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H) represents a distinct phenotype among solid tumors characterized by frequent frameshift mutations resulting in the generation of neoantigens that are highly immunogenic. Seminal studies identified that dMMR/MSI-H tumors are exquisitely sensitive to immune checkpoint inhibitors, which has dramatically improved outcomes for patients harboring dMMR/MSI-H tumors. Nevertheless, many patients develop resistance to single-agent immune checkpoint blockade, prompting the need for improved therapeutic options for this patient population. In this review, we highlight key studies examining the efficacy of PD1 inhibitors in the metastatic and neoadjuvant setting for patients with dMMR/MSI-H tumors, describe resistance mechanisms to immune checkpoint blockade, and discuss novel treatment approaches that are currently under investigation for dMMR/MSI-H tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Sarah Cannon Research Institute, Nashville, TN, USA. Electronic address: vivek.subbiah@scri.com.
Förderung
- NCI
Zitieren
APA
Bhamidipati, D., & Subbiah, V. (2023). Tumor-agnostic drug development in dMMR/MSI-H solid tumors. Trends in Cancer, 9(10), 828-839. https://doi.org/10.1016/j.trecan.2023.07.002
Vancouver
Bhamidipati D, Subbiah V. Tumor-agnostic drug development in dMMR/MSI-H solid tumors. Trends in Cancer. 2023;9(10):828-839. doi:10.1016/j.trecan.2023.07.002
BibTeX
@article{Bhamidipati2023,
author = {Bhamidipati, Deepak and Subbiah, Vivek},
title = {Tumor-agnostic drug development in dMMR/MSI-H solid tumors},
journal = {Trends in Cancer},
year = {2023},
volume = {9},
number = {10},
pages = {828--839},
doi = {10.1016/j.trecan.2023.07.002}
}
EUVIMED